Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Glatiramer Acetate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women at least 18 years of age or older~2. Subjects must have a confirmed and documented RRMS diagnosis as defined by the Revised McDonald criteria, with relapse onset disease or a relapsing-remitting disease course~3. Subjects must be ambulatory with a Kurtzke Expanded Disability Status Scale (EDSS) score of 0-5.5 in both the Screening and Baseline visits.~4. Subjects must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment \[intravenous (IV), intramuscular (IM) and/or per os (PO)\] or adrenocorticotrophic hormone (ACTH), 60 days prior to randomization.~5. Subjects must be treated with Glatiramer Acetate (GA) 20mg/mL QD SC injection for a minimum of 6 months prior to screening.~6. Women of child-bearing potential must practice an acceptable method of birth control \[acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or a double-barrier method (condom or diaphragm with spermicide)\].~7. Subjects must be able to sign and date a written informed consent prior to entering the study.~8. Subjects must be willing and able to comply with the protocol requirements for the duration of the study~Exclusion Criteria:~1. Subject has any contraindication to Glatiramer Acetate therapy~2. Subjects with progressive forms of multiple sclerosis (MS).~3. Subjects with Neuromyelitis Optica (NMO).~4. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.~5. Concomitant use of other disease modifying drug for MS ((Fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), Teriflunomide (Aubagio®) or intravenous immunoglobulin (IVIG)) within 6 months prior to screening~6. Previous use of mitoxantrone, cladribine, alemtuzumab, rituximab, natalizumab.~7. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.~8. Previous total body irradiation or total lymphoid irradiation.~9. Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.~10. Pregnancy or breastfeeding.~11. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG and abnormal laboratory tests. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.~12. Subjects who underwent endovascular treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI).~13. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GA 20 mg/mL every day (Type: ACTIVE_COMPARATOR): Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
- GA 40 mg/mL 3 times a week (Type: EXPERIMENTAL): Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).